How new medicines effect prevention or treatment
We hold exceptional competence in pharmacodynamic assessments of metabolic diseases under new medicines
The dramatic growth of obesity in association with its metabolic, cardiovascular, and mutagenic comorbidities has inspired basic and clinical research and increased our understanding of the molecular pathways driving these diseases.
CRS is a highly experienced, strong, and reliable partner in the early and advanced clinical assessment of investigational drugs or medical devices for the prevention or treatment of obesity, metabolic syndrome, diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), etc., – in brief: in the indication of cardiometabolic and cardiovascular diseases.
Through our in-house medical and regulatory specialists, CRS offers a comprehensive service starting from preparing a powerful and reliable study design, throughout a high quality conduct of the trial in our own or external study sites, up to data management, statistical analysis and medical writing. Our continuous efforts to grow our volunteers and patients database, as well as an established network of collaborating supportive medical specialists and office based doctors are the guarantee of a powerful study recruitment.
Our experienced scientists can provide particular support in the preparation of manuscripts to be placed in high ranked scientific journals, or for the presentation at international scientific meetings. Several hundred papers published in international peer reviewed journals are proof of our outstanding expertise in this therapeutic area.
Below please find some details about the disease course and about our huge armamentarium of pharmacodynamic assessments:
We are consistently extending our medical diagnostic armamentarium to offer highly reliable scientific methods for the assessment of pharmacodynamic effects of new treatments.
In recent years, important breakthrough medical device techniques were achieved in the area of drug application and biosignal monitoring. CRS has a profound regulatory and clinical experience in the performance of medical device studies.
Studies performed at CRS cover the assessment of drug application devices, point of care testing, continuous biosignal monitoring, as well as the implantation of subcutaneous application systems or biological sensors.